IXICO has provided a trading update for the year to September 2024, noting that despite expanding its opportunities pipeline, longer contracting cycles and clinical trial initiation postponements both within FY24 and into FY25, have resulted in lower anticipated revenues for FY24E. IXICO now sees FY24E revenues between £5.2-5.9m (Cavendish previous estimate £6.5m) with an equivalent impact on FY25E. We have set our revenue expectations in-line with the new revenue guidance and updated our foreca ....
13 Mar 2024
IXICO - Trading update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
IXICO - Trading update
IXICO Plc (IXI:LON) | 7.0 0 0.0% | Mkt Cap: 3.38m
- Published:
13 Mar 2024 -
Author:
Chris Donnellan -
Pages:
8
IXICO has provided a trading update for the year to September 2024, noting that despite expanding its opportunities pipeline, longer contracting cycles and clinical trial initiation postponements both within FY24 and into FY25, have resulted in lower anticipated revenues for FY24E. IXICO now sees FY24E revenues between £5.2-5.9m (Cavendish previous estimate £6.5m) with an equivalent impact on FY25E. We have set our revenue expectations in-line with the new revenue guidance and updated our foreca ....